Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well tolerated in obese female subjects. The study will also provide information on how much ZGN-433 gets into the blood, how long does it stay in the body, and how it affects other biological markers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zafgen, Inc.
• Treatments: CKD732

Criteria

Inclusion Criteria:

• Obese, otherwise healthy females

• Post menopausal or infertile

• Weight ≥ 50 kg

• BMI ≥ 32 and ≤ 45 kg/m2

Exclusion Criteria:

• Use of weight loss agents in the past month

• History of eating disorder

• History of diabetes or other endocrine disorder

• History of gastric bypass

• Current smokers

• Unstable body weight during the past 3 months